BMEA Biomea Fusion Inc Total Asset Value of Company

BMEA (Biomea) - company brandmark

Biomea Fusion, Inc. (BMEA) management is focused on creating breakthrough therapies for oncology and diabetes by correcting beta-cell function. The business relies on accessible covalent molecule technology, which guarantees massive operating leverage upon commercialization. This market valuation chart for the company on the GURU.Markets platform shows total assets at 55.02, highlighting hidden pricing power due to the high value of the oral medications under development.

BMEA (Biomea Fusion, Inc.) Company Total Assets history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company Biomea (BMEA)

- market value and analyst target forecast:
Stock Price biomeafusion.com|BMEA - Price Target Chart
- market capitalization data:
Market Valuation Biomea Fusion Corp|BMEA - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share Biomea Fusion|BMEA - Book Capitalization|Market Capitalization to Book Value Ratio biomeafusion.com|BMEA - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Biomea Fusion, Inc.|BMEA - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Biomea Fusion Corp|BMEA - Company Aggregate Debts|Debts to Book Capitalization Biomea Fusion Corp|BMEA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Biomea Fusion|Quick Liquidity Indicator biomeafusion.com
- net income and valuation multiples indicators:
BMEA - Net Profit
Fundamental valuation:Biomea Fusion, Inc.
Manufactured products of Biomea Fusion, Inc.

Biomea Fusion, Inc. (BMEA) is scaling resources to develop oral medications for diabetes and metabolic disorders. The dynamics of the company's total assets reflect the aggregate of property and liabilities calculated reversely via the ROA ratio. Growth in this indicator signals an expanding base for future insurance payments but increases requirements for capital efficiency. The stability of the range confirms a resilient financial foundation as the company prepares for the commercialization of its innovations.

Key competitors

ascendispharma.com (ASND) - Company Total Assets|Aggregate Company Assets Madrigal Pharmaceuticals, Inc.|Corcept Therapeutics Inc. - Total Asset Value of Company|Company Total Assets RYTM|AKRO (Akero Corp) - Aggregate Asset Value|Company Total Assets MTSR (Metsera Inc)|Company Total Assets moonlaketx.com MLTX|CRNX - Aggregate Company Assets|Aggregate Asset Value NAMS (NewAmsterdam Pharma Company)|Soleno (SLNO) - Aggregate Company Assets|Cumulative Company Assets Amicus Corp|ETNB (89bio, Inc.) - Company Total Assets|Company Total Assets agios.com|Cumulative Company Assets GPCR (Structure Therapeutics Inc.)|MDXG (MiMedx Group Inc) - Aggregate Asset Value|Aggregate Company Assets Rezolute Corp RZLT|LXRX - Cumulative Company Assets|MBX Biosciences Inc - Company Total Assets|Company Assets altimmune.com|AARD (Aardvark Therapeutics) - Cumulative Company Assets|SGMT: Aggregate Business Assets|BIOA (BioAge Labs Inc.) - Company Total Assets|Company Total Assets Quince|Company Total Assets GUTS|Aggregate Company Assets VTVT (vtvtherapeutics.com)|Aggregate Company Assets Agape ATP ATPC|Pluristem Therapeutics (PLUR) - Company Assets|SYBX - Aggregate Company Assets|LPCN: Aggregate Company Assets|MTNB: Company Total Assets|SPRB - Company Total Asset Base|Aggregate Company Assets Galecto|Carmell Corp. (CTCX) - Company Total Asset Base|Aggregate Company Assets Lumos Pharma Corp (LUMO)|Cumulative Company Assets Organovo Corp ONVO|Company Total Assets RDUS (Radius Recycling, Inc.)